Fromkin Andrew J. reported option exercise involving 77,181 derivative units of Immunovant, Inc. at $0.00 for $0 on May 28, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed May 29, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
77,181Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
May 28, 2026Option exercise
Filed
May 29, 2026, 4:04 PM ET1-day reporting delay
Accession
0001341896-26-000004Code M · Transaction 94193
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 28, 2026Sell11,483$32.64−$374,805.12Trade 94189
May 28, 2026Sell210,468$33.56−$7,063,306.08Trade 94190
May 28, 2026Option exercise31,668$0.00$0Trade 94191
May 28, 2026Option exercise71,492$0.00$0Trade 94192
May 28, 2026Option exercise16,260$0.00$0Trade 94194
May 28, 2026Option exercise31,668$4.99$158,023.32Trade 94185
May 28, 2026Option exercise71,492$7.94$567,646.48Trade 94186
May 28, 2026Option exercise77,181$8.43$650,635.83Trade 94187
May 28, 2026Option exercise16,260$14.70$239,022Trade 94188
10 transaction rows in this filing. Joint filers share the same rows.

IMVT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IMVT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −19%1w ago +2.5%1d ago +0.3%
Returns since7d −6.5%30d +17%90d180d1y

Footnotes in full

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 - $33.035 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 - $33.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3: Reflects an award of stock options to purchase Common Shares that is fully vested.